Quantum Genomics Announces Result of Annual General Meeting
PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, informs its shareholders that all proposed resolutions were duly passed at the Annual General Meeting of shareholders and governance held today, June 27.
All resolutions were passed almost unanimously, demonstrating shareholders’ support of the Board of Directors' guidance, and confidence in the continued strategic execution by the company.
In parallel with this Annual General Meeting, the Board of Directors was informed of the resignation of director Jean-Paul Kress from the Board, a position he has held since June 2018. This resignation follows his appointment on June 24 as Chief Executive Officer of MorphoSys, which is incompatible with the exercise of his mandate with Quantum Genomics.
The Board of Directors of Quantum Genomics is now composed of four members, including Jean-Philippe Milon, whose appointment as Director of the Company was approved by the General Meeting today.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit , or follow us on and
Contact information
| Quantum Genomics | |
| Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | | Marc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | |
| So Bang (Europe) | |
| Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | | Samuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | |
| LifeSci (USA) | |
| Dan Ferry Financial Communications +1 (617) 535-7746| | Michael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | |
